CONTEXT AND OBJECTIVE: Nausea and vomiting are major inconveniences for patients undergoing chemotherapy. Despite standard preventive treatment, chemotherapy-induced nausea and vomiting (CINV) still occurs in approximately 50% of these patients. In an attempt to optimize this treatment, we evaluated the possible effects of carbamazepine for prevention of CINV.
INTRODUCTION
Nausea and vomiting are major inconveniences for patients undergoing cancer therapy. These symptoms, which are both common and stressful, are reported by almost half of such patients, either as a consequence of the illness itself, or as a treatment side effect. 1 They have a strikingly negative impact on these patients' functional, emotional, social and nutritional status, ultimately leading to impairment of quality of life. 2, 3 Several factors have been implicated in development of chemotherapy-induced nausea and vomiting (CINV), i.e. the intrinsic emetogenicity of some chemotherapeutic agents, either alone or in combination. 2, 4, 5 CINV is classified according to the timing of the occurrence: acute -occurs and resolves within the first 24 hours after chemotherapy; or delayedoccurs after the first 24 hours after chemotherapy administration. 5, 6 Because of the severity of the acute phase, this has been more often targeted in therapeutic intervention studies. However, although the symptoms in the delayed period are less marked than those observed in acutely started nausea and vomiting, its course can be more protracted, resulting in poor hydration and nutrition control, in addition to poor performance status. 7, 8 According to the American Society of Clinical Oncology (ASCO) guidelines for antiemetic management in cancer patients, the standard preventive treatment for CINV is based on selective 5-HT3-receptor antagonists (5HT3AR), corticosteroids and neurokinin-1-receptor antagonists (NK1AR), combined to match the intensity of chemotherapy-induced vomiting. [9] [10] [11] [12] [13] [14] Despite the use of such therapy, approximately 50% of patients still present CINV. 15 However, treatment with these three drugs has a high cost and some of them are unavailable in centers where healthcare funding is provided by the government. In most Brazilian cities, for instance, cancer patients covered by the national healthcare system have no sponsorship for use of either 5HT3RA or NK1RA while being treated in outpatient clinics. In this setting, because medicines are unaffordable for most of these patients, CINV control is even more poorly accomplished.
Efforts to improve CINV prevention have led to investigation of other drugs that can be added to the standard treatment, thus retaining the effectiveness of antiemetics at lower cost. With this purpose, Cruz et al. developed a phase II randomized trial in which they demonstrated that the preventive antiemetic action of gabapentin increased when it was included in the combined treatment during the first cycle of highly emetogenic chemotherapy.
Although the mechanism of action of gabapentin has not been well clarified, this trial suggested that anticonvulsant drugs could be promising for prevention of CINV. 16 Carbamazepine was reported by Strohscheer and Borasio as being completely successful in combating CINV in one patient with meningeal carcinomatosis.
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OBJECTIVE
In the present study, the primary objective was to evaluate the possible effects of carbamazepine in preventing nausea and vomiting induced by highly emetogenic chemotherapy. The secondary objective was to evaluate the side effects of this treatment and its possible influence on patients' quality of life. All patients received the standard antiemetic treatment that was available, which was based on intravenous ondansetron (8 mg), dexamethasone (10 mg) and ranitidine (50 mg) before chemotherapy infusion, followed by oral dexamethasone (4 mg), twice a day on days 2 and 3. Carbamazepine was added to this treatment in accordance with the following schedule: one tablet (200 mg) four times a day on the third day before chemotherapy; one tablet twice a day on the second day before chemotherapy; and one tablet three times a day starting on the day before chemotherapy and continuing until the fifth day after chemotherapy.
METHODS
The patients were asked to record vomiting episodes on diary cards, starting on the day of chemotherapy infusion (0 h) and continuing until the morning of day 6 (120 h). In case of need, participants were free to take a "rescue therapy", and the components of this were also to be recorded. The rescue medications included 5HT3RA, phenothiazines, butyrophenones and domperidone.
Complete prevention of nausea and vomiting was defined as the absence of any episode of these events and no use of rescue medication. Symptoms were defined as acute (occurring during the first 24 hours after chemotherapy), delayed (occurring from day 2 to day 5 after chemotherapy) or overall (occurring over the full 120 hours of the study). 18, 19 Since NK1AR is not provided to Brazilian patients through the public healthcare system, this drug was not used.
The patients filled out the Functional Living Index-Emesis (FLIE) questionnaire on days 1 and 6, as backing for measurement of the impact of CINV on their quality of life. 18 Adverse events were recorded up to the visit on day 6 after chemotherapy.
Considering that there is a lack of evidence regarding the efficacy of anticonvulsants for CINV prevention, Simon's optimal two-stage design 19 was used. Based on the previous trial by
Cruz et al. 16 at our institution, which resulted in a 42.5% control rate in the placebo group, we used a control rate < 50% as the null hypothesis to be tested and a rate > 70% as the alternative hypothesis, since the previous trial showed a 20% benefit from associating gabapentin. The initial end point to be pursued was full control for a minimum of 9 patients out of the 15 in the first stage of the study. Fulfillment of this aim would maintain accrual of an additional 28 patients as a second phase. At the end of the study, in accordance with its design, achievement of complete control in 27 or more patients would be required to reject the null hypothesis. This design had 80% power while maintaining an α error rate of 5%. Summary statistics, including means, standard deviations and medians, were generated for continuous variables.
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RESULTS
Twelve patients were enrolled in the first phase of the study.
These patients were continuously recruited and were all women who had been assigned to receive a highly emetogenic chemotherapeutic regimen of doxorubicin and cyclophosphamide for treatment of breast cancer (100%). The mean age was 48 years ( Table 1) . Two patients were excluded because of refusal to sign the consent statement and opioid use during the study period.
Three patients could not complete the intended treatment due to the advent of untoward manifestations before starting chemotherapy: two presented vomiting before chemotherapy infusion and one had excessive (grade 3) somnolence.
The primary objective of the study was not accomplished, since seven patients proved unresponsive to their properly taken trial treatment throughout the intended time span. Since this finding precluded the alternative hypothesis (> 70%), the study was discontinued. Other adverse events are displayed in Table 2 .
Acute complete control failed in all cases. One patient (10%) achieved acute control of vomiting and this same patient also achieved delayed complete protection (10%). Rescue medications were necessary for nine patients (90%) ( Table 3) .
There was no impact on patients' quality of life, according to results from the FLIE questionnaire.
DISCUSSION
The present study showed that carbamazepine was ineffective for CINV prevention. All patients failed to attain complete control of their symptoms, and most (90%) needed rescue medications.
Moreover, carbamazepine was associated with more side effects than expected, such as somnolence and dizziness, in addition to induction of vomiting before chemotherapy infusion onset in approximately 20% of the patients. At our institution, Cruz et al. conducted a prospective, double-blinded, placebo-controlled study that showed that adding gabapentin to the standard preventive antiemetic treatment for moderately and highly emetogenic chemotherapy was effective (65% vs. 42.5%; P = 0.04). 16 Their trial demonstrated that the acute complete control rate and use of gabapentin were independent factors for achieving an overall complete response.
These results suggested that gabapentin might be a cost-effective well-tolerated alternative to NK1RA, with a safety profile similar to that of the placebo. However, despite the anticonvulsant action of carbamazepine, this drug failed to relieve symptoms in our study, given that nausea and vomiting were not curbed in any of the participants, and that this drug was even hazardous to 30% of Further studies will be needed in order to better understand why carbamazepine hinders nausea and vomiting in meningeal carcinomatosis patients but, contradictorily, is disappointing in unaffected patients.
Phase III studies have already shown that benzodiazepines and olanzapine are effective for improving control over CINV when combined with standard treatment based on 5HT3RA and corticosteroids. [22] [23] [24] In the present study, we used Simon's optimal two-stage design because of the lack of evidence regarding carbamazepine use for preventing CINV. This is an innovative methodology for investigating nausea and vomiting, and its main advantage is that it avoids exposure of too many patients to an ineffective treatment. It should be reappraised in future pilot trials concerning prevention of CINV. 19, 25 Furthermore, other comparative studies with larger samples may be necessary to corroborate these data and evaluate the safety of carbamazepine.
CONCLUSION
Carbamazepine failed to prevent CINV and also presented a deleterious side-effect profile among the patients studied. Based on these data, carbamazepine is not advisable as an antiemetic medication for patients undergoing chemotherapy outside of experimental settings.
